Half year 2022 results

Significant progress against post-COVID-19 growth strategy to offset expected decline in COVID-19 sales

Paris, France and Camberley, UK – 29 September 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the six months ended 30 June 2022.

https://novacyt.com/wp-content/uploads/2022/09/Novacyt-H1-2022-Unaudited-financial-results-ENGLISH.pdf